This project aims to understand CAR T cell trafficking in the brain. We are comparing delivery of CAR T cells into the lateral ventricle or cisterna magna, and comparing to those delivered into the tumor itself. We are also seeking optimal dosing strategies as 

(Funded by Dept of Defense)

Using a syngeneic model of DIPG/DMG, we aim to uncover how the immune system interacts with CAR T cells, both to augment the signal (and potential toxicity), as well as hinder the T cells. This work will help us build better T cells that can act more efficiently in the CNS.

(Funded by NIH/NCI)

We are working in collaboration with BioNTech and their technology utilizing mRNA to boost CAR T cells directed against the tumor antigen CLDN6. CLDN6 is over-expressed is several pediatric brain tumors including ATRT and chordoma.

(Funded by Matthew Larson Foundation and Foederer Award)

DIPG/DMG patients are treated with radiation as standard frontline therapy. We are investigating how radiation therapy, and specifically a new form of radiation called FLASH radiotherapy changes DIPG/DMG cells and the immune microenvironment, and can potentiate the activity of our CAR T cells. 

(Funded by Cell and Gene Therapy Seed Grant)

Collaborating with the Phillips Lab, we are using CRISPR screens to investigate epigenetic mechansisms of resistance to CAR T cell therapy in DMG

(Funded by CHOP-Penn Synergy grant)

Using big data from the CBTN/OpenPedCan and immunopeptidomics, we are developing pipelines and exploring new targets for CAR T cell therapy in CNS tumors

(Funded by Gilbert Foundation)